论文部分内容阅读
目的:观察威麦宁胶囊联合卡培他滨治疗晚期乳腺癌的临床效果及安全性。方法:回顾性分析2013年1月—2016年6月在本院乳腺外科治疗的100例晚期乳腺癌患者。所有患者均服用威麦宁胶囊,一次6~8粒,3次/d。卡培他滨1250 mg/m2,分2次口服,d1~d14,治疗两周,停药1周,21 d为1个治疗周期,连续治疗2个周期以上。观察患者的治疗周期、无进展生存期(PFS)、总体生存期(OS)以及药物不良反应。结果:患者的平均治疗周期为6.5(2~12)个周期;平均治疗时间为4.5(1.4~8.4)个月;平均PFS为6.8(1.5~15.3)个月;平均OS为14.9(2.5~21.1)月。最常见的不良反应为贫血、骨髓抑制、高血压。总缓解率为80%(95%CI 1.78~5.69)。其中10例完全缓解;70例部分缓解。结论:威麦宁胶囊联合卡培他滨治疗晚期乳腺癌具有一定的疗效,耐受性高,值得在临床大力推广应用。
Objective: To observe the clinical efficacy and safety of Weimaining capsule combined with capecitabine in the treatment of advanced breast cancer. Methods: Retrospective analysis of 100 patients with advanced breast cancer who underwent surgical treatment in our hospital from January 2013 to June 2016. All patients received Weimaining capsules, once 6-8 capsules, 3 times a day. Capecitabine 1250 mg/m2 was given orally 2 times, d1 to d14, for 2 weeks, 1 week off, 21 days for 1 treatment cycle, continuous treatment for more than 2 cycles. Observe the patient’s treatment cycle, progression-free survival (PFS), overall survival (OS), and adverse drug reactions. RESULTS: Patients had an average treatment period of 6.5 (2 to 12) cycles; mean treatment time was 4.5 (1.4 to 8.4) months; mean PFS was 6.8 (1.5 to 15.3) months; mean OS was 14.9 (2.5 to 21.1). )month. The most common adverse reactions were anemia, bone marrow suppression, and hypertension. The total remission rate was 80% (95% CI 1.78 to 5.69). Among them, 10 cases were completely relieved; 70 cases were partially relieved. Conclusion: Weimaining capsule combined with capecitabine has a certain curative effect on advanced breast cancer and has high tolerance. It is worthy of being widely used in clinical practice.